FRANKLIN, Tenn., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that it will host a virtual Clover Assistant Showcase on Thursday, October 12, 2023 at 12:00 p.m. Eastern Time. The event will feature informative product demonstrations, followed by a live Q&A session with Clover executives and key members of the Clover Assistant team.
"Healthcare is at a pivotal moment, and Clover Assistant is our answer to the challenges we face," said Andrew Toy, Chief Executive Officer of Clover Health. "Software-assisted doctors focusing on the early detection of disease aren't just a nice-to-have; they're critical. We believe that early intervention leads to healthier Medicare patients and, by extension, lowers costs for society at large."
“We are thrilled to share some of the outcomes we’re driving for real patients through Clover Assistant’s ability to help support clinicians in effectively managing chronic conditions earlier, and the potential impact of our technology on the broader healthcare system,” said Conrad Wai, Chief Technology Officer of Clover Health.
Event Webcast Details:
Clover Health has always been at the forefront of using technology to improve healthcare outcomes. Clover Assistant is built on a robust data infrastructure that continuously learns from real-world patient interactions. Clover Assistant’s goal is to provide actionable insights to doctors, thereby transforming the way primary care is delivered. During the Clover Assistant Showcase, company leaders will discuss key product features and capabilities, and demonstrate real-world examples of how clinicians are leveraging the platform to improve care delivery and coordination for their Clover patients. Demonstrations will include:
Forward-looking Statements
This document contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied including due to risk factors described in Clover Health’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) and Clover Health’s other filings with the SEC. We do not undertake to update any such statements.
About Clover Health
Clover Health (Nasdaq: CLOV) is a physician enablement company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. We operate two distinct lines of business: Insurance and Non-Insurance. Through our Insurance line of business, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. Our Non-Insurance line of business similarly aims to reduce cost-of-care while enhancing the quality of care for patients enrolled in Original Medicare.
Press Contact:
Andrew Still-Baxter
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Ryan Schmidt
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.21 |
Daily Change: | -0.12 -3.60 |
Daily Volume: | 11,425,107 |
Market Cap: | US$1.320B |
March 03, 2025 February 27, 2025 February 05, 2025 January 07, 2025 November 06, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load